Obvious Management Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Obvious Management Services’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$42.4M	Sell	3,985,087 -1,992,544	-33%	-$20.2M	100%	1
2022 Q2	$48.7M	Hold	5,977,631	–	–	100%	1
2022 Q1	$42.8M	Hold	5,977,631	–	–	100%	1
2021 Q4	$102M	Buy	+5,977,631	New	+$112M	87.1%	1

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DOFI

DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return

Obvious Management Services's RXRX Position: Q3 2022 in Review

Obvious Management Services reduced its Recursion Pharmaceuticals (RXRX) stake by 33% in Q3 2022, selling an estimated $20.2M and leaving 3,985,087 shares worth $42.4M. The position accounts for 100% of the portfolio, ranked #1.

Obvious Management Services first reported a position in RXRX in Q4 2021 and has held it in 4 quarters since. The position peaked at $102M in Q4 2021. 146 funds tracked by Wall St. Rank hold RXRX as of Q3 2022.

Obvious Management Services held 3,985,087 shares of Recursion Pharmaceuticals worth $42.4M as of Q3 2022.
Obvious Management Services sold 1,992,544 Recursion Pharmaceuticals shares in Q3 2022, an estimated $20.2M.
Recursion Pharmaceuticals made up 100% of Obvious Management Services's portfolio in Q3 2022, its #1 holding.
Obvious Management Services first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 4 quarters since.
Obvious Management Services's Recursion Pharmaceuticals position peaked at $102M in Q4 2021.
146 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2022.

Based on Obvious Management Services's 13F filing for Q3 2022, filed 14 Nov 2022.